EDCTP Alumni Network

Fostering excellence and collaboration in the next generation of researchers

Call Senior Fellowship (SF)
Programme EDCTP2
Start Date 2018-04-01
End Date 2023-03-31
Project Code TMA2016SF1508
Status Active

Title

Pharmacogenomics Research And Clinical Excellence in the Treatment of Infectious Diseases in African

Host Organisation

Institution Country
African Institute of Biomedical Science & Technology (AIBST) Zimbabwe

Sites

Wilkins Infectious Disease Hospital (Harare)

Phd Study

Title University Start Date End Date
Medical Biochemistry and Biophysics Karolinska Institute, Sweden 1995-01-02 1995-11-30

Students Supervised

Type Name Title University Start Date End Date
Phd Nyarai Shoko Ms UCT 2014 2017
PhD Benjamin Ebeshi Dr AOU 2011 2011
MPhil Lovejoy Nleya Mr UZ 2012 2016
PhD Britta Kjellander Dr Gothenburg Univ 2010 2010
MPhil Winnie Muzorandi Mrs UZ 2011 2015
PhD Nicholas Mwaura Mr UCT 2011 2014

Publications

262
187
205
154
119
171
129
126
128
129
Call Senior Fellowship (SF)
Programme EDCTP1
Start Date 2012-11-01
End Date 2014-12-31
Project Code TA.2011.40200.052
Status Completed

Title

A prospective study to evaluate a pharmacogenetic-guided dosing algorithm based on patient CYP2B6 genotype compared to the empirical standard dose in the safe and efficacious use of efavirenz in HIV/AIDS patients in Zimbabwe

Objectives

Primary Objectives: 1. To compare efavirenz exposure levels in patients in whom the initiation dose is based on a pharmacogenetic algorithm with those in patients given the standard dose 2. To compare HIV viral load suppression and CD4 counts in patients in whom efavirenz dose is based on a pharmacogenetic algorithm with those in patients given the standard dose 3. To compare the incidences and severity of efavirenz associated adverse drug reactions; liver function, skin hypersensitivity reactions and central nervous system (CNS) effects in patients in whom the efavirenz dose is based on a pharmacogenetic algorithm with those given the standard dose 4. To validate the CYP2D6 genotyping method for use in the clinical study

Host Organisation

Institution Country
African Institute of Biomedical Science and Technology (AiBST) Zimbabwe

Study Design

Prospective randomised controlled trial

Sites

Wilkins Infectious Disease Hospital (Harare)
Chitugwiza Hospital, Opportunistic Infections Unit (Chitugwiza)

Results & Outcomes

HIV/AIDS and TB cohort in Zimbabwe. We have conclusively shown that the CYP2B6*6 genotype is predictive of high concentrations of Project Porftolio Page 333 of 622 efavirenz and predisposition to CNS sides effects and require only 200 mg of the drug instead of the standard 600 mg a day. We have also shown that for the other patients heterozygous, that those carrying one defect CYP2B6 allele and those without a defect should only be given 400 mg of efavirenz a day. Our findings are supported by a recent major study, ENCORE, which demonstrated the non-inferiority of 400 mg to the 600 mg efavirenz dose. This therefore represents the climax of our study which medicines control regulatory authorities should now consider towards revising the use of this drug. We have now engaged the Medicines Control Authority of Zimbabwe (MCAZ) and the National AIDS Council (NAC). We have also been on radio stations explaining our results to the public, an outreach that has been well received and patients phoned in expressing their appreciation of having the reason for their ADRs explained based on our study. The work has also resulted in secondary of achievements such as: (1) Establishment of a Clinical Trial Research Group whose purpose is to critically discuss the design and execution of clinical studies in African settings. (2) Four publications (3) Initiation of a Clinical Trial Unit (CTC) at one of the major hospitals in Zimbabwe, Chitungwiza General Hospital, for the conduct of Phase I Clinical Studies. (4) The completion of PhD studies and successful defence of the thesis in December 2014, by Milcah Dhoro on Pharmacogenetics of Efavirenz

Current Organisation

African Institute of Biomedical Science and Technology (AIBST)

Current Job Title

Chief Scientific Officer

Awards

2018 HUGO (Human Genome Organisation) International Africa Award for innovative research contribution in genomics in Africa – 5 000 USD.
2017 1st Prize Innovation Award, Gauteng Accelator Program (GAP) South Africa – 500 000 Rands.
2017 Research Council of Zimbabwe Robert Gabriel Mugabe Outstanding Research Award (Awarded by the President of Zimbabwe through RCZ) – 15 000 USD
2014 Certificate of Excellence in recognition of pioneering work in the field of Forensic DNA Services in Zimbabwe (Awarded by the Vice-President of Zimbabwe)
1996 Certificate of Distinction in Biochemistry, President Robert Mugabe, Government of Zimbabwe (Awarded by the President of Zimbabwe) – 10 000 USD.

Students Supervised

Type Name Title University Start Date End Date
MPhil Lovejoy Nleya Mr University of Zimbabwe 2012 2016
PhD Nyarai Shoko Miss University of Cape Town 2014 2014
Molecular Diagnostics Vanessa Chasi Miss National University of Science & Technology 2014 2015
Drug-Herb Interactions Winnie Muzorandi Miss University of Zimbabwe 2011 2015
PGx Milcah Dhoro Ms UZ 2011 2014
Molecualr Virology Benjamin Chimkangara Mr UZ 2012 2015
Medicinal Chem. Nicholas Mwaura Mr UCT 2011 2014
ADME/Med. Chem. Roslyn Thelingwani Miss UCT 2008 2012
PGx Margaret Oluka Miss UoN 2006 2012
ADME/Med. Chem. Britta Kjellander Miss Gothenburg Univ 2010 2010
PGx Benjamin Ebeshi Mr OAU 2011 2011
PGx Alice Matimba Miss UCT 2009 2009
HIV Drug Resistance Justen Manasa Mr UZ 2008 2008
PGx Christopher Nyakutira Mr UZ 2008 2008
Drug-Herb Interactions Luther Gwaza Mr UZ 2008 2008
PK Simbarashe Zvada Mr UZ 2011 2011
PGx Emmanuel Chigutsa Mr UZ 2010 2010
ADMET Roslyn Thelingwani Miss UZ 2007 2007
ADMET Roslyn Thelingwani Miss UZ 2005 2005
ADMET AnnCharlotte Egnell Ms Gothenburg Univ. 2002 2002
ADMET Lovisa Afzelius Ms Gothenburg Univ. 1999 1999
ADMET Anna Åhgren Ms Gothenburg Univ. 2001 2001
ADMET/PK Tashinga Bapiro Mr UZ 2004
ADMET/Med Chem. Lovisa Afzelius Miss Uppsala Univ 2004 2004
ADMET Rose Hayeshi Miss UZ 2008 2008

Memberships

Role Committee/board Start Date End Date
Member and Secretary IUPHAR (International Union of Pharmacology) Drug Metabolism and Transporters Section 2014
Member IUPHAR (International Union of Pharmacology) Pharmacogenetics Section 2014
International Advisor Malaysian Society for the Advancement of Pharmacogenomics (MSAP 2005 2010
President The African Society of Drug Metabolism and Development 2009
Member Laboratory Committee of the Medicines Control Authority of Zimbabwe (MCAZ) 2004 2014
Fellow and Dean of the College of Life Sciences Zimbabwe Academy of Science (ZAS) 2007 2016
Chairperson & Founding Member African Pharmacogenomics Consortium 2003
AAS Governing Council Southern African Representative The African Academy of Sciences Governing Council 2017
President African Pharmacogenomics Consortium 2018

Education

Institution Degree Year
Uinversity of Zimbabwe, Zimbabwe BSc (Hons) (Biochemistry), University of Zimbabwe 1989-05-04
University of Zimbabwe, Zimbabwe DPhil (Biochemistry), 1994-02-04
Karolinska Institute, Sweden PhD (Medical Biochemistry and Biophysics 1995-02-05
,

Areas Of Specialisation

Human Immuno-deficiency Virus (HIV)

Grants

Grant Code:
Source of funding:
Gauteng Accelerator Program (GAP)
Amount:
35332.32
Role:
Principal Investigator
Start Date:
2017-01-01
End Date:
2018-01-01
Grant Code:
Source of funding:
Norvatis
Amount:
110000.00
Role:
Principal Investigator
Start Date:
2012-01-01
End Date:
2014-01-01
Grant Code:
Source of funding:
WHO-TDR
Amount:
60000.00
Role:
Principal Investigator
Start Date:
2010-01-01
End Date:
2012-01-01
Grant Code:
Source of funding:
TWAS
Amount:
10000.00
Role:
Principal Investigator
Start Date:
2008-01-01
End Date:
2009-01-01
Grant Code:
Source of funding:
IUPHAR
Amount:
5000.00
Role:
Principal Investigator
Start Date:
2002-01-01
End Date:
2002-01-01
Grant Code:
Source of funding:
Merck Master Service Agreement.
Amount:
130000.00
Role:
Principal Investigator
Start Date:
2013-01-01
End Date:
2015-01-01
Grant Code:
Source of funding:
AstraZeneca
Amount:
239131.25
Role:
Principal Investigator
Start Date:
2003-01-01
End Date:
2007-01-01
Grant Code:
Source of funding:
Norvatis
Amount:
150000.00
Role:
Principal Investigator
Start Date:
2016-01-01
End Date:
2016-01-01
Grant Code:
Source of funding:
ISP
Amount:
129216.60
Role:
Principal Investigator
Start Date:
2012-01-01
End Date:
2017-01-01
Grant Code:
TA.2011.40200.052
Source of funding:
European and Developing Countries Clinical Trials Partnership (EDCTP)
Amount:
Role:
Principal Investigator
Start Date:
2012-11-01
End Date:
2014-12-31
Grant Code:
Source of funding:
ISP
Amount:
180000.00
Role:
Principal Investigator
Start Date:
2018-01-01
End Date:
2020-01-01
Grant Code:
Source of funding:
SANBIO BIOFISAII
Amount:
9893.05
Role:
Start Date:
2016-01-01
End Date:
2018-01-01
Grant Code:
Source of funding:
European Union (EU)-AntiMal.
Amount:
360000.00
Role:
Principal Investigator
Start Date:
2008-01-01
End Date:
2011-01-01
Grant Code:
Source of funding:
ISP
Amount:
114859.20
Role:
Principal Investigator
Start Date:
2012-01-01
End Date:
2014-01-01
Grant Code:
Source of funding:
AstraZeneca
Amount:
216000.00
Role:
Principal Investigator
Start Date:
2017-01-01
End Date:
2018-01-01
Grant Code:
Source of funding:
Wellcome Trust
Amount:
38500.00
Role:
Start Date:
2016-01-01
End Date:
2016-01-01
Grant Code:
Source of funding:
ISP
Amount:
19130.50
Role:
Principal Investigator
Start Date:
2008-01-01
End Date:
2008-01-01
Grant Code:
Source of funding:
BrfArM
Amount:
350000.00
Role:
Start Date:
2017-01-01
End Date:
2020-01-01
Grant Code:
Source of funding:
SANBIO BIOFISAII
Amount:
5000.00
Role:
Principal Investigator
Start Date:
2002-01-01
End Date:
2002-01-01
Grant Code:
Source of funding:
NIH
Amount:
300000.00
Role:
Co Principal Investgator
Start Date:
2018-01-01
End Date:
2022-01-01
Grant Code:
Source of funding:
ISP
Amount:
92652.50
Role:
Principal Investigator
Start Date:
2009-01-01
End Date:
2011-01-01
Grant Code:
Source of funding:
Saving African Families Enterprises
Amount:
50000.00
Role:
Principal Investigator
Start Date:
2014-01-01
End Date:
2015-01-01
Grant Code:
Source of funding:
AstraZeneca
Amount:
10000.00
Role:
Principal Investigator
Start Date:
2002-01-01
End Date:
2002-01-01
Grant Code:
Source of funding:
WHO-TDR
Amount:
70000.00
Role:
Principal Investigator
Start Date:
2008-01-01
End Date:
2009-01-01
Grant Code:
Source of funding:
WHO-TDR
Amount:
36000.00
Role:
Principal Investigator
Start Date:
2007-01-01
End Date:
2007-01-01
Grant Code:
Source of funding:
European Union. EDCTP
Amount:
64000.00
Role:
Principal Investigator
Start Date:
2007-01-01
End Date:
2011-01-01
Grant Code:
Source of funding:
European and Developing Countries Clinical Trials Partnership (EDCTP)
Amount:
500000.00
Role:
Principal Investigator
Start Date:
2018-01-01
End Date:
2022-01-01

Publications

Authors:
L Afzelius, I Zamora, M Ridderström, TB Andersson, A Karlén, CM Masimirembwa , 129
Date:
2009-05-05
Journal:
Molecular pharmacology 59 (4)
Content:
Identifiers:
Authors:
Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y.
Date:
2012-03-06
Journal:
Eur J Clin Pharmacol. 2012 Mar;68(3):267-71.
Content:
Identifiers:
Authors:
CM Masimirembwa, R Thompson, TB Andersson , 154
Date:
2001-05-05
Journal:
Combinatorial chemistry & high throughput screening 4 (3)
Content:
Identifiers:
Authors:
Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL
Date:
2008-09-29
Journal:
Biopharm Drug Dispos. 2008 Sep;29(6):324-34.
Content:
Identifiers:
Authors:
Kjellander B, Masimirembwa CM, Zamora I.
Date:
2007-05-31
Journal:
J Chem Inf Model. 2007 May-Jun;47(3):1234-47
Content:
Identifiers:
Authors:
Adzu B, Mustapha KB, Masimirembwa C, Obodozie O, Kirim RA, Gamaniel KS. Avicenna J Phytomed
Date:
2013-03-03
Journal:
2013 Summer;3(3):201-
Content:
Identifiers:
Authors:
XQ Li, A Björkman, TB Andersson, LL Gustafsson, CM Masimirembwa , 205
Date:
1996-05-05
Journal:
European journal of clinical pharmacology 59 (5-6
Content:
Identifiers:
Authors:
Dandara C, Huzair F, Borda-Rodriguez A, Chirikure S, Okpechi I, Warnich L, Masimirembwa C
Date:
2014-12-18
Journal:
OMICS. 2014 Dec;18(12):733-9
Content:
Identifiers:
Authors:
Gutierrez MM, Pillai G, Felix S, Romero F, Onyango KO, Owusu-Agyei S, Asante KP, Barnes KI, Sinxadi P, Allen E, Abdulla S, Masimirembwa C, Munyoro M, Yimer G, Gebre-Mariam T, Spector J, Ogutu B
Date:
2017-04-05
Journal:
Clin Pharmacol Ther; 10.1002/cpt.695. [Epub ahead of print]
Content:
Identifiers:
Authors:
TE Bapiro, AC Egnell, JA Hasler, CM Masimirembwa , 126
Date:
2001-05-05
Journal:
Drug Metabolism and disposition 29 (1),
Content:
Identifiers:
Authors:
Chimukangara B, Gwanzura L, Mitchell R, Katzenstein D, Masimirembwa C
Date:
2014-12-05
Journal:
Curr HIV Res. 2014;12(5):309-16
Content:
Identifiers:
Authors:
Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM
Date:
2009-06-03
Journal:
Drug Metab Dispos. 2009 Jun;37(6):1286-94
Content:
Identifiers:
Authors:
Matimba A, Tybring G, Chitereka J, Zinyama-Gutsire R, Dandara C, Bürén E, Dhoro M, Masimirembwa C
Date:
2016-04-15
Journal:
Biopreserv Biobank. 2016 Apr 15. [Epub ahead of print] PMID: 27082894
Content:
Identifiers:
Authors:
Grobler L, Grobler A, Haynes R, Masimirembwa C. Thelingwani R, Steenkamp P, Steyn HS
Date:
2014-03-24
Journal:
Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):313-25
Content:
Identifiers:
Authors:
Adzu B, Masimirembwa C, Mustapha KB, Thelingwani R, Kirim RA, Gamaniel KS
Date:
2015-03-04
Journal:
Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):115-8.
Content:
Identifiers:
Authors:
Bonn B, Masimirembwa CM, Castagnoli N Jr
Date:
2010-01-04
Journal:
Drug Metab Dispos. 2010 Jan;38(1):187-99.
Content:
Identifiers:
Authors:
CM Masimirembwa, C Otter, M Berg, M Jönsson, B Leidvik, E Jonsson, ... , 129
Date:
1999-05-05
Journal:
Drug Metabolism and Disposition 27 (10),
Content:
Identifiers:
Authors:
Manasa J, Musabaike H, Masimirembwa C, Burke E, Luthy R, Mudzori J
Date:
2007-03-14
Journal:
Clin Vaccine Immunol. 2007 Mar;14(3):293-8.
Content:
Identifiers:
Authors:
Simms V, Dauya E, Dakshina S, Bandason T, McHugh G, Munyati S, Chonzi P, Kranzer K, Ncube G, Masimirembwa C, Thelingwani R, Apollo T, Hayes R, Weiss HA, Ferrand RA. PLoS Med
Date:
2018-07-25
Journal:
e1002360. doi: 10.1371/journal.pmed.1002360. eCollection
Content:
Identifiers:
Authors:
Adigun RA, Martincigh B, Nyamori VO, Omondi B, Masimirembwa C, Simoyi RH.
Date:
2014-09-14
Journal:
Dalton Trans. 2014 Sep 14;43(34):12943-51
Content:
Identifiers:
Authors:
Johansson T, Jurva U, Grönberg G, Weidolf L, Masimirembwa C
Date:
2009-03-03
Journal:
Drug Metab Dispos. 2009 Mar;37(3):571-9.
Content:
Identifiers:
Authors:
Jurva U, Holmén A, Grönberg G, Masimirembwa C, Weidolf L
Date:
2008-04-21
Journal:
Chem Res Toxicol. 2008 Apr;21(4):928-35.
Content:
Identifiers:
Authors:
Dhoro M, Ngara B, Kadzirange G, Nhachi C, Masimirembwa C
Date:
2013-09-11
Journal:
Curr HIV Res. 2013 Sep;11(6):481-90.
Content:
Identifiers:
Authors:
Thelingwani R, Masimirembwa C.
Date:
2014-10-10
Journal:
Curr Drug Metab. 2014;15(10):942-52
Content:
Identifiers:
Authors:
Zawaira A, Matimba A, Masimirembwa C
Date:
2008-06-18
Journal:
Pharmacogenet Genomics. 2008 Jun;18(6):467-76
Content:
Identifiers:
Authors:
CM Masimirembwa, C Otter, M Berg, M Jönsson, B Leidvik, E Jonsson, TB Andersson , 119
Date:
1999-05-05
Journal:
Drug Metabolism and Disposition 27 (10)
Content:
Identifiers:
Authors:
Ongarora DS, Strydom N, Wicht K, Njoroge M, Wiesner L, Egan TJ, Wittlin S, Jurva U, Masimirembwa CM, Chibale K.
Date:
2015-09-01
Journal:
Bioorg Med Chem. 2015 Sep 1;23(17):5419-32.
Content:
Identifiers:
Authors:
7. Rhead R, Masimirembwa C, Cooke G, Takaruza A, Nyamukapa C, Mutsimhi C, Gregson S
Date:
2016-12-14
Journal:
PLoS One. 2016 Dec 14;11(12):e0167852. doi: 10.1371/journal.pone.0167852. eCollection 2016.
Content:
Identifiers:
Authors:
Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C.
Date:
2015-03-27
Journal:
BMC Pharmacol Toxicol. 2015 Mar 27;16:4.
Content:
Identifiers:
Authors:
XQ Li, A Björkman, TB Andersson, M Ridderström, CM Masimirembwa , 262
Date:
2002-01-02
Journal:
Pharmacology and Experimental Therapeutics 300 (2)
Content:

Amodiaquine (AQ) metabolism to N-desethylamodiaquine (DEAQ) is the principal route of disposition in humans. Using human liver microsomes and two sets of recombinant human cytochrome P450 isoforms (from lymphoblastoids and yeast) we performed studies to identify the CYP isoform(s) involved in the metabolism of AQ. CYP2C8 was the main hepatic isoform that cleared AQ and catalyzed the formation of DEAQ. The extrahepatic P450s, 1A1 and 1B1, also cleared AQ and catalyzed the formation of an unknown metabolite M2. TheKm and Vmaxvalues for AQ N-desethylation were 1.2 μM and 2.6 pmol/min/pmol of CYP2C8 for recombinant CYP2C8, and 2.4 μM and 1462 pmol/min/mg of protein for human liver microsomes (HLMs), respectively. Relative contribution of CYP2C8 in the formation of DEAQ was estimated at 100% using the relative activity factor method. Correlation analyses between AQ metabolism and the activities of eight hepatic P450s were made on 10 different HLM samples. Both the formation of DEAQ and the clearance of AQ showed excellent correlations (r2 = 0.98 and 0.95) with 6α-hydroxylation of paclitaxel, a marker substrate for CYP2C8. The inhibition of DEAQ formation by quercetin was competitive withKi values of 1.96 for CYP2C8 and 1.56 μM for HLMs. Docking of AQ into the active site homology models of the CYP2C isoforms showed favorable interactions with CYP2C8, which supported the likelihood of an N-desethylation reaction. These data show that CYP2C8 is the main hepatic isoform responsible for the metabolism of AQ. The specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP2C8 activity.

Identifiers:
Authors:
Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN, Masimirembwa CM
Date:
2008-07-08
Journal:
Eur J Hum Genet. 2008 Jul;16(7):780-3.
Content:
Identifiers:
Authors:
Ericsson T, Masimirembwa C, Abelo A, Ashton M
Date:
2012-04-02
Journal:
Drug Metab Lett. 2012;6(4):247-57
Content:
Identifiers:
Authors:
Afzelius L, Raubacher F, Karlén A, Jørgensen FS, Andersson TB, Masimirembwa CM, Zamora I
Date:
2004-11-11
Journal:
Drug Metab Dispos. 2004 Nov;32(11):1218-29.
Content:
Identifiers:
Authors:
Thelingwani R, Bonn B, Chibale K, Masimirembwa C
Date:
2014-10-10
Journal:
Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1313-24.
Content:
Identifiers:
Authors:
Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, McHugh G, van Dijk JH, Bwakura-Dangarembizi M, Ndung'u T, Masimirembwa C, Phelps B, Amzel A, Ojikutu BO, Walker BD, Ndhlovu CE
Date:
2015-12-14
Journal:
PLoS One. 2015 Dec 14;10(12):
Content:
Identifiers:
Authors:
Njuguna NM, Masimirembwa C, Chibale K
Date:
2012-03-23
Journal:
J Nat Prod. 2012 Mar 23;75(3):507-13.
Content:
Identifiers:
Authors:
CM Masimirembwa, U Bredberg, TB Andersson , 128
Date:
2003-05-05
Journal:
Clinical pharmacokinetics 42 (6),
Content:
Identifiers:
Authors:
4. Makadzange AT, Boyd FK, Chimukangara B, Masimirembwa C, Katzenstein D, Ndhlovu CE
Date:
2017-05-03
Journal:
J Clin Microbiol. 2017 Jul;55(7):2172-2179. doi: 10.1128/JCM.00176-17
Content:
Identifiers:
Authors:
Chimukangara B, Manasa J, Mitchell R, Nyabadza G, Katzenstein D, Masimirembwa C
Date:
2016-10-26
Journal:
AIDS Res Hum Retroviruses
Content:
Identifiers:
Authors:
Ongarora DS, Gut J, Rosenthal PJ, Masimirembwa CM, Chibale K
Date:
2012-08-01
Journal:
Bioorg Med Chem Lett. 2012 Aug 1;22(15):5046-5010.
Content:
Identifiers:
Authors:
Bonn B, Masimirembwa CM, Aristei Y, Zamora I
Date:
1998-11-02
Journal:
Drug Metab Dispos. 2008 Nov;36(11):2199-210
Content:
Identifiers:
Authors:
Cotton RG; 2006 Human Variome Project, Appelbe W, Auerbach AD, Becker K, Bodmer W, Boone DJ, Boulyjenkov V, Brahmachari S, Brody L, Brookes A, Brown AF, Byers P, Cantu JM, Cassiman JJ, Claustres M, Concannon P, Cotton RG, den Dunnen JT, Flicek P, Gibbs R, Hall J, Hasler J, Katz M, Kwok PY, Laradi S, Lindblom A, Maglott D, Marsh S, Masimirembwa CM, Minoshima S, de Ramirez AM, Pagon R, Ramesar R, Ravine D, Richards S, Rimoin D, Ring HZ, Scriver CR, Sherry S, Shimizu N, Stein L, Tadmouri GO, Taylor G, Watson M
Date:
2007-04-03
Journal:
Nat Genet. 2007 Apr;39(4):433-6.
Content:
Identifiers:
Authors:
Thelingwani RS, Dhansay K, Smith P, Chibale K, Masimirembwa CM
Date:
2012-10-12
Journal:
Xenobiotica. 2012 Oct;42(10):989-1000.
Content:
Identifiers:
Authors:
Soko ND, Masimirembwa C, Dandara C. OMICS.
Date:
2016-09-20
Journal:
2016 Sep;20(9):498-509. doi: 10.1089/omi.2016.0114.PMID: 27631189
Content:
Identifiers:
Authors:
Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C
Date:
2009-01-05
Journal:
Hum Genomics. 2009 Jan;3(2):169-90.
Content:
Identifiers:
Authors:
Afzelius L, Zamora I, Masimirembwa CM, Karlén A, Andersson TB, Mecucci S, Baroni M, Cruciani G.
Date:
2004-02-12
Journal:
J Med Chem. 2004 Feb 12;47(4):907-14.
Content:
Identifiers:
Authors:
Thelingwani R, Leandersson C, Bonn B, Smith P, Chibale K, Masimirembwa C
Date:
2015-09-04
Journal:
Xenobiotica. 2015 Sep 4:1-7. [Epub ahead of print] PMID: 26338168
Content:
Identifiers:
Authors:
Jurva U, Holmén A, Grönberg G, Masimirembwa C, Weidolf L
Date:
2008-04-21
Journal:
Chem Res Toxicol. 2008 Apr;21(4):928-35.
Content:
Identifiers:
Authors:
Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM
Date:
2005-11-07
Journal:
Eur J Clin Pharmacol. 2005 Nov;61(10):755-61.
Content:
Identifiers:
Authors:
Adeagbo BA, Bolaji OO, Olugbade TA, Durosinmi MA, Bolarinwa RA, Masimirembwa C. J Clin
Date:
2016-10-14
Journal:
Pharm Ther. 2016 Oct;41(5):546-51. doi: 10.1111/jcpt.12424. PMID: 27426203
Content:
Identifiers:
Authors:
Chigorimbo-Murefu NT, Njoroge M, Nzila A, Louw S, Masimirembwa C, Chibale K
Date:
2012-12-04
Journal:
Future Med Chem. 2012 Dec;4(18):2325-36.
Content:
Identifiers:
Authors:
Chibale K, Guantai EM, Masimirembwa C.
Date:
2011-03-03
Journal:
Future Med Chem. 2011 Mar;3(3):257-61
Content:
Identifiers:
Authors:
Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL
Date:
2006-09-29
Journal:
Eur J Pharm Sci. 2006 Sep;29(1):70-81.
Content:
Identifiers:
Authors:
Masimirembwa C, Dandara C, Leutscher PD
Date:
2016-10-20
Journal:
OMICS. 2016 Oct;20(10):575-580. PMID: 27627692
Content:
Identifiers:
Authors:
Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C
Date:
2014-06-10
Journal:
Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):769-85.
Content:
Identifiers:
Authors:
Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C. Eur J
Date:
2008-04-07
Journal:
Clin Pharmacol. 2008 Apr;64(4):357-65.
Content:
Identifiers:
Authors:
Persson KP, Ekehed S, Otter C, Lutz ES, McPheat J, Masimirembwa CM, Andersson TB
Date:
2006-01-23
Journal:
Pharm Res. 2006 Jan;23(1):56-69
Content:
Identifiers:
Authors:
Dhoro M, Nhachi C , Masimirembwa C. , Dhoro M, Nhachi C , Masimirembwa C. Technological and cost comparison of cytochrome P450 2B6 (516G>T) genotyping methods in routine clinical practice. African Journal of Biotechnology. 2013.12(19): 2706-2710 (DOI: 10.5897/AJB2013.12043)
Date:
2013-01-01
Journal:
African Journal of Biotechnology
Content:
Identifiers:
Authors:
Awortwe C, Bouic PJ, Masimirembwa CM, Rosenkranz B
Date:
2014-07-07
Journal:
Drug Metab Lett. 2014 Jul;7(2):83-95.
Content:
Identifiers:
Authors:
C Nyakutira, D Röshammar, E Chigutsa, P Chonzi, M Ashton, C Nhachi, CM Masimirembwa , 171
Date:
2008-05-05
Journal:
European journal of clinical pharmacology 64 (4)
Content:
Identifiers:
Authors:
C MASIMIREMBWA, I PERSSON, L BERTILSSON, J HASLER , 187
Date:
2009-05-05
Journal:
British journal of clinical pharmacology 42 (6)
Content:
Identifiers:
Authors:
Mao M, Matimba A, Scordo MG, Gunes A, Zengil H, Yasui-Furukori N, Masimirembwa C, Dahl ML
Date:
2009-09-10
Journal:
Pharmacogenomics. 2009 Sep;10(9):1447-55.
Content:
Identifiers:

Send a Message